Thiazolides: a new class of antiviral drugs

Bibliography

• Rossignol JF, Cavier R. 2-benzamido 5-nitrothiazoles. Chem Abstr 1975;84:28216n
   Google Scholar
• Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int J Clin Pharmacol Ther Toxicol 1984;22:63-72
   PubMed Web of Science ®Google Scholar
• Liu LX, Weller PF. Antiparasitic drugs. N Engl J Med 1996;334:1178-84
   PubMed Web of Science ®Google Scholar
• Katz M. Anthelmintics. Current concepts in the treatment of helminthic infections. Drugs 1986;32:358-71
   PubMed Web of Science ®Google Scholar
• Zhong HL, Cao WJ, Rossignol JF, et al. Albendazole in nematode, cestode, trematode and protozoan (Giardia) infections. Chin Med J 1986;11:912-5
   Google Scholar
• Euzéby J, Prom Tep S, Rossignol JF. Expérimentation des propriétés anthelminthiques de la nitazoxanide chez le chien, le chat et les ovins. Revue de Médecine Vétérinaire 1980;131:687-96
   Web of Science ®Google Scholar
• Cavier R, Rossignol JF. Etude pharmacologique de diverses associations d'anthelminthiques chez la souris. Revue de Médecine Vétérinaire 1982;133:779-83
   Web of Science ®Google Scholar
• Rossignol JF, Cavier R. New derivatives of 2-benzamido 5-nitrothiazoles. US Patent 3950351; 1976
   Google Scholar
• Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am J Trop Med Hyg 1984;33:511-2
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Maisonneuve H. Albendazole: a new concept in the treatment of intestinal helminthiasis. Gastroentérol Clin. Biol 1984;8:569-76
   Google Scholar
• Fox L, Saravolatz LD. Nitazoxanide a new thiazolide antiparasitic agent. Clin Infect Dis 2006;40:1173-80
   Web of Science ®Google Scholar
• Romark Laboratories. Alinia® (nitazoxanide) prescribing information. June, 2005
   Google Scholar
• Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of hepatitis B and C. Future Microbiol 2008;3:539-45
   PubMed Web of Science ®Google Scholar
• Korba BE, Mueller AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res 2008;77:56-63
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Abou-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide in treating severe rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial. Lancet 2006;368:124-9
   PubMed Web of Science ®Google Scholar
• Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double blind placebo controlled trial. Aliment Pharmacol Ther 2006;24:1423-30
   PubMed Web of Science ®Google Scholar
• Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis In press
   Google Scholar
• Hoffman PS, Sisson G, Croxen MA, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductasess of Helicobacter pylori, selected anaerobic bacteria and parasites and Campilobacter jejuni. Antimicrob Agents Chemother 2007;51:868-76
   PubMed Web of Science ®Google Scholar
• Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002;511:133-44
   PubMed Web of Science ®Google Scholar
• Santoro MG, Ciucci A, Gianferritti P, et al. Thiazolides: a new class of broad-spectrum antiviral drugs targeting virus maturation. Antivir Res 2007;74:A31
   Google Scholar
• Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J Biol Chem. In press
   Google Scholar
• Stockis A, De Bruyn S, Gengler C, Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int J Clin Pharmacol Ther 2002;40:221-7
   PubMed Web of Science ®Google Scholar
• Adagu IS, Nolder D, Warhurst D, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002;49:103-111
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic bacteria. Antimicrob Agents Chemother 2006;50:112-7
   Google Scholar
• Müller J, Rühle G, Müller N, et al. In vitro effects of thiazolides on Giardia lamblia WB C6 cultured axenically and in co-culture with Caco2 cells. Antimicrob Agents Chemother 2006;50:162-70
   PubMed Web of Science ®Google Scholar
• Korba BE, Elazar M, Lui P, et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology 2008;48(Suppl):356A
   Google Scholar
• Korba BE, Elazar M, Lui P, et al. Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines. Antimicrob Agents Chemother 2008;52:4069-71
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Broekhuysen J, Stockis A, Lins RL, et al. Nitazoxanide: Pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38:387-94
   PubMed Web of Science ®Google Scholar
• Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int J Clin Pharmacol Ther 2002;40:213-20
   PubMed Web of Science ®Google Scholar
• Vets E, Rossignol JF, Jackson AS. Effect of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health Syst Pharm. 2009;66:838-42
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Kabil SM, El-Gohary YM, et al. Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008;28:574-80
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Elfert A, El-Gohary Y, Keefe EB. Improved virologic response in chronic hepatitis C genotype 4 patients treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-62
   PubMed Web of Science ®Google Scholar
• Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther 2006;24:887-94
   PubMed Web of Science ®Google Scholar
• Bacon BR, Shiffman ML, Lim JK, Berman A, Rustgi VK, Keeffe EB; STEALTH C-3 Investigators. Phase II randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in hepatitis C genotype 1 naïve patients: interim analysis shows increase in EVR. J Hepatol In press
   Google Scholar
• Shiffman ML, Ahmed A, Jacobson IM, Pruitt RE, Keeffe EB; STEALTH C-2 Investigators. Phase II randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis. J Hepatol In press
   Google Scholar
• Keeffe EB, Rossignol JF, Elfert A, et al. Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C. Hepatol Int. 2009;3:49
   Google Scholar
• Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology 2008;48:344A-5A
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a propective randomized double-blind placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:103-6
   PubMed Web of Science ®Google Scholar
• Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002;360:1375-80
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Kabil SM, Younis AM, El-Gohary Y. Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immunocompetent adults and adolescents from the Nile delta of Egypt. Clin Gastroenterol Hepatol 2006;4:320-4
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica/dispar: a double blind placebo controlled study of nitazoxanide. J Infect Dis 2001;184:381-4
   PubMed Web of Science ®Google Scholar
• Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409-15
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amebiasis. Trans R Soc Trop Med Hyg 2007;101:1025-31
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide in the treatment of Clostridium difficile associated diseases. Clin Infect Dis 2006;43:421-7
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6
   PubMed Web of Science ®Google Scholar
• Abubakar I, Aliyu SG, Arumugam C, et al. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol 2007;63:387-93
   PubMed Web of Science ®Google Scholar
• Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and ef?cacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitits C: results of a placebo-controlled study. J Hepatol 1996;25:591-8
   PubMed Web of Science ®Google Scholar
• Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006;101:842-7
   PubMed Web of Science ®Google Scholar